Stephan Bildat

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Rüdiger Hehlmann, Michael Lauseker, Susanne Saußele et al. · Leukemia · 2017 · 339 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer

Joachim von Pawel, U. Gatzemeier, Jean-Louis Pujol et al. · Journal of Clinical Oncology · 2001 · 233 citations

Medicine, Oncology, Pharmacology +11

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

Rüdiger Hehlmann, Astghik Voskanyan, Michael Lauseker et al. · Leukemia · 2020 · 92 citations · Full text

Life Sciences, Hematology, Oncology +16

Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results

Georgios Stamatis, Wilfried Eberhardt, Georg Stüben et al. · The Annals of Thoracic Surgery · 1999 · 90 citations · Full text

Medicine, Oncology, Surgery +14

10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45Gy (1.5Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)—A multicenter phase-II trial (CISTAXOL)

Wilfried Eberhardt, Thomas Gauler, C. Lepéchoux et al. · Lung Cancer · 2013 · 25 citations

Medicine, Oncology, Surgery +15